research peptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-18 and is reviewed periodically as new material appears.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Acetylated heptapeptide form |
| Monoisotopic mass | 888.5 Da | Average mass about 889 Da |
| Appearance | White to off-white solid | Usually supplied as lyophilised powder |
| Solubility class | Highly water soluble | Also dissolves in aqueous buffers |
| Common synonyms | Tbeta4 fragment, thymosin beta-4 (17-23) | Refer to the same sequence |
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
signal transduction The process by which a chemical, electrical, or mechanical signal is converted into a cellular response, or the transmission or propagation of such a signal through a cell as a series of molecular events known as a signaling pathway. For example, the extracellular interaction of a hormone, growth factor, or some other chemical agonist with a specific cell surface receptor can trigger a cascade of sequential biochemical reactions which propagate through the cell membrane and into the cytoplasm, provoking the synthesis of second messengers and leading to amplification of the signal or activation of other pathways. Other modes of transduction involve agonists which diffuse across the membrane freely, eliciting intracellular changes without amplification, or rapid shifts in cell polarity which transmit electrical impulses, such as those that cause the axons of neural cells to release neurotransmitters at synapses.
During his life in retirement, from 1959 up to his death in 1973, Tolkien received steadily increasing public attention and literary fame. In 1961 his friend C. S. Lewis even nominated him for the Nobel Prize in Literature. The sales of his books were so profitable that he regretted that he had not chosen early retirement. In a letter in 1972 he deplored having become a cult figure, but admitted that "even the nose of a very modest idol ... cannot remain entirely untickled by the sweet smell of incense!" Fan attention became so intense that Tolkien had to take his phone number out of the public directory; eventually he and Edith moved to Bournemouth, which was then a seaside resort patronized by the British upper middle class. Tolkien's status as a best-selling author gave them easy entry into polite society, but Tolkien deeply missed the company of his fellow Inklings. Edith, however, was overjoyed to step into the role of a society hostess, which had been the reason that Tolkien selected Bournemouth in the first place. The genuine and deep affection between Ronald and Edith was demonstrated by their care about the other's health, in details like wrapping presents, in the generous way he gave up his life at Oxford so she could retire to Bournemouth, and in her pride in his becoming a famous author. They were also united by love for their children and grandchildren. In his retirement Tolkien was a consultant and translator for The Jerusalem Bible, published in 1966.
Mexico has both public and private universities, with wide variation in terms of cost, academic performance, and organization. The most reputable and largest university, the National Autonomous University of Mexico (UNAM), is publicly funded and virtually free, while also independent from the government. Instituto Politécnico Nacional is a federally-administered public university. Several public state universities follow an autonomous model similar to UNAM, including Universidad de Guadalajara and Universidad Autónoma de Nuevo León. However, these state universities do not receive as much public funding, which means higher tuition fees.
== Signs and symptoms == Initially, the symptoms of biliary atresia are indistinguishable from those of neonatal jaundice, a usually harmless condition commonly seen in infants. However, infants with biliary atresia develop progressive conjugated jaundice, pale white stools, dark urine, and an enlarged palpable liver. Some infants fail to thrive as there will be a degree of fat and fat-soluble vitamin malabsorption (e.g. Vitamin K). This may cause a bleeding tendency. Eventually, and usually after 2 months, cirrhosis with portal hypertension will develop. If left untreated, biliary atresia can lead to liver failure. Unlike other forms of jaundice, however, biliary-atresia-related cholestasis mostly does not result in kernicterus, a form of brain damage resulting from liver dysfunction. This is because in biliary atresia, the liver, although diseased, is still able to conjugate bilirubin, and conjugated bilirubin is unable to cross the blood–brain barrier.
Sources: en.wikipedia.org
The chain's origin can be traced to the Dwarf Grill (now the Dwarf House), a restaurant opened by S. Truett Cathy (the chain's former chairman and CEO) in 1946 in the Atlanta suburb of Hapeville, Georgia. The original store was located near the Ford Motor Company Atlanta Assembly Plant, a source of many of the restaurant's patrons for years. It was later remodeled, reopening in 2022. In 1961, after 15 years in the fast-food business, Cathy found a pressure fryer that could cook a chicken sandwich in the same time it took to cook a hamburger. Following this discovery, he registered the name Chick-fil-A, Inc. The company's trademarked slogan, "We Didn't Invent the Chicken, Just the Chicken Sandwich," refers to their flagship menu item, the Chick-fil-A chicken sandwich. Though Chick-fil-A was the first national chain to make a fast, fried chicken sandwich its flagship item, it has been shown that Cathy's claim to have "invented the chicken sandwich" is false. From 1964 to 1967, the sandwich was licensed to over fifty eateries, including Waffle House and the concession stands of the new Houston Astrodome. The Chick-Fil-A sandwich was withdrawn from sale at other restaurants when the first dedicated location opened in 1967, in the food court of the Greenbriar Mall in Atlanta. The chain expanded in the 1970s and early 1980s by opening new locations in suburban malls' food courts. The first freestanding location was opened April 16, 1986, on North Druid Hills Road in Atlanta, Georgia, and the company began to focus more on stand-alone units rather than food courts.
=== German === Alliance of Transylvania Saxons - Founded as the Siebenburger Bund on July 5, 1902. On August 31 of the same year became the Central Verband der Siebenburger Sachsen. Adopted current name in 1965. Headquarters in Cleveland, lodges called branches; there were 43 in 1978. The national convention meets annually. Membership was open to those "of Transylvanian Saxon birth or descent thereof, or married to a Saxon of descendent thereof, or of German birth or descendent thereof" ages 16–60 who were also healthy enough to pass the insurance requirements and of sound mind and habits and high moral caliber. The Transylvanian Saxon Juniors Association was founded in 1931 to provide insurance for youth. The TSJA also conducts track and field, swim meets golf, softball, and bowling. Saturday German study classes for youth began in 1925. No rituals, but local Branches have their brief initiation ceremonies. Sponsored the Saxon Basketball League in 1927. Charitable activities included helping repatriate Saxon POWs in Siberia to Saxony in 1918; in 1920 it sent $33,000 to Saxon National School in Hermannstadt, a school for orphans, now has its orphan fund. Sent $22,000 in 1970–1971 to Romania for flood relief. 9,871 members in 1967, 8,629 members in 1976 8,892 members in 1989. Membership had stabilized at around 10,000 for decades. Ancient Order of Freesmiths - Claimed to be descended from the Vehmgericht of medieval Germany. The first known lodge in the United States was founded in Baltimore in 1865.
=== Bone === Despite having a lower than optimum drug penetration into bone ratio of 10–20%, flucloxacillin appears effective in treating osteomyelitis. Depending on local guidance, it may be used in the treatment of infection of joints while waiting for culture results.
Sources: en.wikipedia.org
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.
It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.
Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.